Sarepta Therapeutics Inc. (SRPT)

143.92
39.00 37.00
NASDAQ : Health Technology
Prev Close 105.24
Open 160.00
Day Low/High 135.72 / 176.50
52 Wk Low/High 32.36 / 107.49
Volume 15.24M
Avg Volume 1.22M
Exchange NASDAQ
Shares Outstanding 65.53M
Market Cap 6.70B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

A Weak Close Is Going to Have a Significant Impact on Sentiment

A Weak Close Is Going to Have a Significant Impact on Sentiment

It is important for the bulls that the indices close near the highs of the day.

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.

These Pockets of Momentum Are Where the Action Is in This Market

These Pockets of Momentum Are Where the Action Is in This Market

Until that action dies it is difficult to be too bearish.

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

Market Bifurcation: Individual Stocks Are Acting Better Than the Indices

This underperformance is being caused by pockets of weakness in bigger-cap names.

Market Acting Like the Worst Is Over

Market Acting Like the Worst Is Over

Stocks are following through on Friday's rebound for now.

Sarepta And Invitae Expand Partnership To Advance Clinical Research In Duchenne Muscular Dystrophy

--The program helps clinicians identify patients who may be eligible for Sarepta's clinical trials--

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Buffett's Apple Move Doesn't Do Much to Shift the Negative Technical Pattern

Finding good setups in individual stocks is still challenging as there simply isn't a lot of strong momentum.

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

3 Sectors I'm Trading Right Now as a Market Rotation Takes Hold

Rotational action is the main theme Wednesday and good opportunities are out there.

Biotechs Take the Lead This Morning

Biotechs Take the Lead This Morning

Whether this market continues to bounce is going to depend a great degree on the FAANG names.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Announces Launch Of Route 79, The Duchenne Scholarship Program

-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy --

Big Cap Tech Was the Play of the Day

Big Cap Tech Was the Play of the Day

With few catalysts for the markets, Tuesday's special election for a Pennsylvania congressional seat could set the tone this week.

There's Plenty of Positive Action But It's a Little Overheated

There's Plenty of Positive Action But It's a Little Overheated

I'll be watching for entry points to develop this afternoon.

There's No Big Rush for the Indices at this Point

There's No Big Rush for the Indices at this Point

The best way to deal with the struggling market is selective stock picking and good defense.

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

Focused on Two Sectors

Focused on Two Sectors

If we have a little consolidating action here the buyers will start pushing again.

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic

What drives the trading action are structural issues, not macroeconomic news events or political drama.

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

First Duchenne Muscular Dystrophy Patient Dosed In Systemic Microdystrophin Gene Therapy

Duchenne Organizations Led by Parent Project Muscular Dystrophy Help Fund Next Step in Cutting-Edge Treatment

TheStreet Quant Rating: D (Sell)